HealthcareSmall capRs 3,397 crRs 5.8 cr traded a day
Close on 10 September 2026
303.35
+1.29%
52-week range35% of the way up
255.30392.10
Market cap
3,397 cr
P/E (TTM)
19.8×
industry 45×
EPS (TTM)
15.34
Revenue YoY
+2.1%
Q1 FY27
Profit YoY
-4.6%
Net margin
20.3%
-1.4pt vs a year ago
Growth trend
-19.6pt
vs last quarter’s YoY
1 month
+0.6%
Below 52w high
29.3%
RSI (14)
55
Daily swing
2.4%
average true range
Volume
2.1×
vs 20-day average
Traded
Rs 6 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Below the median
-3.4%
One-year return
Around the median
-10.3%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+2.1%
Below the 52-week high
from the highest close of the year
-22.6%
1 week
+2.48%
1 month
+0.56%
3 months
−17.42%
6 months
+7.61%
1 year
−10.32%
The read
written from the numbers on this page
The evidence is mixed3 supporting, 4 against, 1 worth knowing
Supporting
matches trading far more than usual, which has beaten the market by +0.46 points over 20 sessions across 53,330 past signals
4 independent kinds of evidence agree today, which is uncommon
priced at 20× earnings against an industry median of 45× — 56% below its peers
Against
trading 3% below its 200-day average
down 10% over twelve months
2 of the scans it matches have historically underperformed the market
net margin has narrowed from 24.2% to 20.3% across four quarters
Worth knowing
revenue grew 2% year on year in the quarter ending 30 June 2026
What would change this read: a close back above 314, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working
Nothing on this side tonight — not in the filings and not in the price.
Needs watching3
Net margin moved from 21.8% to 20.3%.
21.8%20.3%
Trading 3.4% below its 200-day average.
-3.4%
A warning rule fires on it tonight: lost the 200-day line.
Lost the 200-day line
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 1 of these 1 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
4 of 47 matched on 10 Sep
ADVENZYMES matches 4 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
ADVENZYMES trades at 20× trailing earnings, below its median of 24× over this window — 18% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Buyback filings were typically +2.28pt vs the market over the next 5 sessions (n=54)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 2% against the same quarter a year earlier
Going against it
profit dropped 5% year on year
net margin narrowed from 22.3% to 20.3%
revenue rose in 1 of the last 4 quarters
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
190
54
39
3.31
20.3%
Q4 FY26
31 Mar · consolidated
203
60
45
3.84
22.3%
Q3 FY26
31 Dec · consolidated
172
58
43
3.80
25.1%
Q2 FY26
30 Sep · consolidated
185
60
45
3.87
24.2%
Q1 FY26
30 Jun · consolidated
186
55
40
3.57
21.8%
Q4 FY25
31 Mar · consolidated
167
43
27
2.37
16.0%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-2.3%
Versus 200-day average-3.4%
Below 52-week high-22.6%
Above 52-week low+18.8%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)54.7
Higher closes in last 54 of 5
Six-month return+7.61%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.37%
Volume versus 20-day2.1x
Median daily turnoverRs 5.8 cr
Peers
Healthcare · 68 classified companies
ADVENZYMES trades at 19.8× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — cheaper than them, by 56%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.